Protumor vs antitumor functions of IL-17

Journal of Immunology

Volumn 183, Issue 7, 2009, Pages 4169-4175

  Murugaiyan, Gopal ^a   Saha, Bhaskar ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 17;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CYTOTOXICITY; INFLAMMATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TH17 CELL; TUMOR GROWTH; TUMOR REGRESSION; ANIMAL; BIOSYNTHESIS; COMPARATIVE STUDY; HELPER CELL; HUMAN; IMMUNOLOGY; METABOLISM; NEOPLASM; PHYSIOLOGY; SECRETION;

ANIMALS; HUMANS; INTERLEUKIN-17; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 70449715722     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901017     Document Type: Review

References (114)

1. Murugaiyan, G., S. Martin, and B. Saha. 2007. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 28: 467-473. (Pubitemid 350103683)
2. Zitvogel, L., A. Tesniere, and G. Kroemer. 2006. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6: 715-727. (Pubitemid 44453458)
3. Wang, H. Y., and R. F. Wang. 2007. Regulatory T cells and cancer. Curr. Opin. Immunol. 19: 217-223.
4. Murugaiyan, G., S. Basak, and B. Saha. 2006. Reversal of tumor induced dendritic cell paralysis: a treatment regimen against cancer. Curr. Immunol. Rev. 2: 261-272. (Pubitemid 44237215)
5. Kelsall, B. L., E. Stüber, M. Neurath, and W. Strober. 1996. Interleukin-12 production by dendritic cells: the role of CD40-CD40L interactions in Th1 T-cell responses. Ann. NY Acad. Sci. 795: 116-126. (Pubitemid 27029560)
6. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483. (Pubitemid 28292196)
7. Stumbles, P. A., R. Himbeck, J. A. Frelinger, E. J. Collins, R. A. Lake, and B. W. Robinson. 2004. Cutting edge: tumor-specific CTL are constitutively crossarmed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J. Immunol. 173: 5923-5928.
8. + T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549.
9. Curtsinger, J. M., D. C. Lins, and M. F. Mescher. 2003. Signal 3 determines tolerance versus full activation of naive CD8 T cells: dissociating proliferation and development of effector function. J. Exp. Med. 197: 1141-1151.
10. Murugaiyan, G., R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha. 2007. Differential CD40/CD40L expression results in counteracting antitumor immune responses. J. Immunol. 178: 2047-2055. (Pubitemid 46233401)
11. Murugaiyan, G., S. Martin, and B. Saha. 2007. Levels of CD40 expression on dendritic cells dictate tumour growth or regression. Clin. Exp. Immunol. 149: 194-202. (Pubitemid 46897112)
12. Murugaiyan, G., R. Agrawal, G. C. Mishra, D. Mitra, and B. Saha. 2006. Functional dichotomy in CD40 reciprocally regulates effector T cell functions. J. Immunol. 177: 6642-6649. (Pubitemid 44715027)
13. Mathur, R. K., A. Awasthi, P. Wadhone, B. Ramanamurthy, and B. Saha. 2004. Reciprocal CD40 signals through p38MAPK and ERK-1/2 induce counteracting immune responses. Nat. Med. 10: 540-544.
14. Rub, A., R. Dey, M. Jadhav, R. Kamat, S. Chakkaramakkil, S. Majumdar, R. Mukhopadhyaya, and B. Saha. 2009. Cholesterol depletion associated with Leishmania major infection alters macrophage CD40 signalosome composition and effector function. Nat. Immunol. 10: 273-280.
15. Perona-Wright, G., S. J. Jenkins, R. A. O'Connor, D. Zienkiewicz, H. J. McSorley, R. M. Maizels, S. M. Anderton, and A. S. MacDonal. 2009. A pivotal role for CD40-mediated IL-6 production by dendritic cells during IL-17 induction in vivo. J. Immunol. 182: 2808-2815.
16. Zhou, P., and R. A. Seder. 1998. CD40 ligand is not essential for induction of type 1 cytokine responses or protective immunity after primary or secondary infection with histoplasma capsulatum. J. Exp. Med. 187: 1315-1324. (Pubitemid 28189120)
17. Cua, D. J., J. Sherlock, Y. Chen, C. A. Murphy, B. Joyce, B. Seymour, L. Lucian, W. To, S. Kwan, T. Churakova, et al. 2003. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421: 744-748.
18. Rouvier, E., M. F. Luciani, M. G. Mattéi, F. Denizot, and P. Golstein. 1993. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 150: 5445-5456. (Pubitemid 23180658)
19. Yao, Z., S. L. Painter, W. C. Fanslow, D. Ulrich, B. M. Macduff, M. K. Spriggs, and R. J. Armitage. 1995. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 155: 5483-5486.
20. Fossiez, F., O. Djossou, P. Chomarat, L. Flores-Romo, S. Ait-Yahia, C. Maat, J. J. Pin, P. Garrone, E. Garcia, S. Saeland, et al. 1996. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183: 2593-2603.
21. Shi, Y., S. J. Ullrich, J. Zhang, K. Connolly, K. J. Grzegorzewski, M. C. Barber, W. Wang, K. Wathen, V. Hodge, C. L. Fisher, et al. 2000. A novel cytokine receptor-ligand pair: identification, molecular characterization, and in vivo immunomodulatory activity. J. Biol. Chem. 275: 19167-19176.
22. Yao, Z., W. C. Fanslow, M. F. Seldin, A. M. Rousseau, S. L. Painter, M. R. Comeau, J. I. Cohen, and M. K. Spriggs. 1995. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 3: 811-821.
23. Hymowitz, S. G., E. H. Filvaroff, J. P. Yin, J. Lee, L. Cai, P. Risser, M. Maruoka, W. Mao, J. Foster, R. F. Kelley, et al. 2001. IL-17s adopt a cystine knot fold: structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J. 20: 5332-5341.
24. Moseley, T. A., D. R. Haudenschild, L. Rose, and A. H. Reddi. 2003. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 14: 155-174.
25. Gaffen, S. L. 2004. Biology of recently discovered cytokines: IL-17- a unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res. Ther. 6: 240-247.
26. Michel, M. L., D. Mendes-da-Cruz, A. C. Keller, M. Lochner, E. Schneider, M. Dy, G. Eberl, and M. C. Leite-de-Moraes. 2008. Critical role of ROR-γt in a new thymic pathway leading to IL-17-producing invariant NKT cell differentiation. Proc. Natl. Acad. Sci. USA 105: 19845-19850.
27. + T cells. J. Immunol. 182: 5296-5305.
28. O'Brien, R. L., C. L. Roark, and W. K. Born. 2009. IL-17-producing γδT cells. Eur. J. Immunol. 39: 662-666.
29. H17 cells. Nature 453: 1051-1057.
30. Awasthi, A., G. Murugaiyan, and V. K. Kuchroo. 2008. Interplay between effector Th17 and regulatory T cells. J. Clin. Immunol. 28: 660-670.
31. + T helper cells. Cell 126: 1121-1133.
32. Cirée, A., L. Michel, S. Camilleri-Bröet, F. Jean Louis, M. Oster, B. Flageul, P. Senet, F. Fossiez, W. H. Fridman, H. Bachelez, and E. Tartour. 2004. Expression and activity of IL-17 in cutaneous T-cell lymphomas (mycosis fungoides and Sezary syndrome). Int. J. Cancer 112: 113-120.
33. Haudenschild, D., T. Moseley, L. Rose, and A. Reddi. 2002. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J. Biol. Chem. 277: 4309-4316.
34. Zhang, B., G. Rong, H. Wie, M. Zhang, J. Bi, L. Ma, X. Xue G. Wie, X. Liu, and G. Fang. 2008. The prevalence of Th17 cells in patients with gastric cancer. Biochem. Biophys. Res. Commun. 374: 533-537.
35. Kryczek, I., M. Banerjee, P. Cheng, L. Vatan, W. Szeliga, S. Wei, E. Huang, E. Finlayson, D. Simeone, T. H. Welling, et al. 2009. Phenotype, distribution, generation, functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
36. + T-cell axis in patients with breast cancer. Br. J. Cancer 100: 1061-1067.
37. Inozume, T., K. Hanada, Q. J. Wang, and J. C. Yang. 2009. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J. Immunother. 32: 109-117.
38. + IL-17-producing T cells in ovarian cancer. Proc. Natl. Acad. Sci. USA 105: 15505-15510.
39. Dhodapkar, K. M., S. Barbuto, P. Matthews, A. Kukreja, A. Mazumder, D. Vesole, S. Jagannath, and M. V. Dhodapkar. 2008. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 112: 2878-2885.
40. Le Gouvello, S., S. Bastuji-Garin, N. Aloulou, H. Mansour, M. T. Chaumette, F. Berrehar, A. Seikour, A. Charachon, M. Karoui, K. Leroy, et al. 2008. High prevalence of Foxp3 and IL17 in MMR-proficient colorectal carcinomas. Gut 57: 772-779.
41. Wróbel, T., G. Mazur, B. Jazwiec, and K. Kuliczkowski. 2003. Interleukin-17 in acute myeloid leukemia. J. Cell. Mol. Med. 7: 472-474.
42. + T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int. J. Cancer 125: 1372-1379.
43. reg skewing. Clin. Cancer Res. 14: 3254-3261.
44. Steiner, G. E., M. E. Newman, D. Paikl, U. Stix, N. Memaran-Dagda, C. Lee, and M. J. Marberger. 2003. Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate 56: 171-182.
45. Zhu, X., L. A. Mulcahy, R. A. Mohammed, A. H. Lee, H. A. Franks, L. Kilpatrick, A. Yilmazer, E. C. Paish, I. O. Ellis, P. M. Patel, and A. M. Jackson. 2008. IL-17 expression by breast-cancer-associated macrophages: IL-17 promotes invasiveness of breast cancer cell lines. Breast Cancer Res. 10: R95.
46. von Euw, E., T. Chodon, N. Attar, J. Jalil, R. C. Koya, B. Comin-Anduix, and A. Ribas. 2009. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J. Transl. Med. 7: 35.
47. Kato, T., H. Furumoto, T. Ogura, Y. Onishi, M. Irahara, S. Yamano, M. Kamada, and T. Aono. 2001. Expression of IL-17 mRNA in ovarian cancer. Biochem. Biophys. Res. Commun. 282: 735-738.
48. H17 cells in B-cell non-Hodgkin's lymphoma. Cancer Res. 69: 5522-5530.
49. Gounaris, E., N. R. Blatner, K. Dennis, F. Magnusson, M. F. Gurish, T. B. Strom, P. Beckhove, F. Gounari, and K. Khazaie. 2009. T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis. Cancer Res. 69: 5490-5497.
50. Wägsäter, D., S. Löfgren, A. Hugander, and J. Dimberg. 2006. Expression of interleukin-17 in human colorectal cancer. Anticancer Res. 26: 4213-4216.
51. Martin-Orozco, N., Y. Chung, S. H. Chang, Y. H. Wang, and C. Dong. 2009. Th17 cells promote pancreatic inflammation but only induce diabetes efficiently in lymphopenic hosts after conversion into Th1 cells. Eur. J. Immunol. 39: 216-224.
52. + regulatory T cells in small cell lung cancer reflects disease stage. Clin. Cancer Res. 14: 6770-6779.
53. Nam, J. S., M. Terabe, M. J. Kang, H. Chae, N. Voong, Y. A. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, et al. 2008. Transforming growth factor β subverts the immune system into directly promoting tumor growth through interleukin-17. Cancer Res. 68: 3915-3923.
54. Shime H., M. Yabu, T. Akazawa, K. Kodama, M. Matsumoto, T. Seya, and N. Inoue. 2008. Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway. J. Immunol. 180: 7175-7183.
55. + T cells in experimental autoimmune encephalomyelitis and in multiple sclerosis. J. Immunol. 181: 7480-7488.
56. 2 synergistically with interleukin-23 favors human Th17 expansion. Blood.112: 3696-3703.
57. Massagué, J. 2008. TGF-β in cancer. Cell 134: 215-230.
58. Liu, S. J., J. P. Tsai, C. R. Shen, Y. P. Sher, C. L. Hsieh, Y. C. Yeh, A. H. Chou, S. R. Chang, K. N. Hsiao, F. W. Yu, and H. W. Chen. 2007. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-β and interleukin-6. J. Leukocyte Biol. 82: 354-360.
59. Blankenstein, T., and Z. Qin. 2003. The role of IFN-γ in tumor transplantation immunity and inhibition of chemical carcinogenesis. Curr. Opin. Immunol. 15: 148-154.
60. Greenhough, A., H. J. Smartt, A. E. Moore, H. R. Roberts, A. C. Williams, C. Paraskeva, and A. Kaidi. 2009. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386.
61. Kortylewski, M., H. Xin, M. Kujawski, H. Lee, Y. Liu, T. Harris, C. Drake, D. Pardoll, and H. Yu. 2009. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15: 114-123.
62. 2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J. Immunol. 178: 8138-8147.
63. Langowski, J. L., X. Zhang, L. Wu, J. D. Mattson, T. Chen, K. Smith, B. Basham, T. McClanahan, R. A. Kastelein, and M. Oft. 2006. IL-23 promotes tumour incidence and growth. Nature 442: 461-465.
64. Aggarwal, S., N. Ghilardi, M. H. Xie, F. J. de Sauvage, and A. L. Gurney. 2003. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278: 1910-1914. (Pubitemid 36801431)
65. Wang, Y. Q., S. Ugai, O. Shimozato, L. Yu, K. Kawamura, H. Yamamoto, T. Yamaguchi, H. Saisho, and M. Tagawa. 2003, Induction of systemic immunity by expression of interleukin-23 in murine colon carcinoma cells. Int. J. Cancer 105: 820-824.
66. Shimozato, O., S. Ugai, M. Chiyo, H. Takenobu, H. Nagakawa, A. Wada, K. Kawamura, H. Yamamoto, and M. Tagawa. 2006. The secreted form of the p40 subunit of interleukin (IL)-12 inhibits IL-23 functions and abrogates IL-23-mediated antitumour effects. Immunology 117: 22-28.
67. Shan, B., L. Yu, O. Shimozato, Q. Li, and M. Tagawa. 2004. Expression of interleukin-21 and -23 in human esophageal tumors produced antitumor effects in nude mice. Anticancer Res. 24: 79-82. (Pubitemid 38279691)
68. Lo, C. H., S. C. Lee, P. Y. Wu, W. Y. Pan, J. Su, C. W. Cheng, S. R. Roffler, B. L. Chiang, C. N. Lee, C. W. Wu, and M. H. Tao. 2003. Antitumor and antimetastatic activity of IL-23. J. Immunol. 171: 600-607.
69. Shan, B. E., J. S. Hao, Q. X. Li, and M. Tagawa. 2006. Antitumor activity and immune enhancement of murine interleukin-23 expressed in murine colon carcinoma cells. Cell. Mol. Immunol. 3: 47-52.
70. Hu, J., X. Yuan, M. L. Belladonna, J. M. Ong, S. Wachsmann-Hogiu, D. L. Farkas, K. L. Black, and J. S. Yu. 2006. Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res. 66: 8887-8896.
71. Jasny, E., M. Eisenblätter, K. Mätz-Rensing, K. Tenner-Racz, M. Tenbusch, A. Schrod, C. Stahl Hennig, V. Moos, T. Schneider, P. Racz, et al. 2008. IL-12-impaired and IL-12-secreting dendritic cells produce IL-23 upon CD154 restimulation. J. Immunol. 180: 6629-6639.
72. Perona-Wright, G., S. J. Jenkins, R. A. O'Connor, D. Zienkiewicz, H. J. McSorley, R. M. Maizels, S. M. Anderton, and A. S. MacDonald. 2009. A pivotal role for CD40-mediated IL-6 production by dendritic cells during IL-17 induction in vivo. J. Immunol. 182: 2808-2815.
73. + T cells. Proc. Natl. Acad. Sci. USA 106: 876-881.
74. Shurin, M. R., Z. R. Yurkovetsky, I. L. Tourkova, L. Balki, and G. V. Shurin. 2002. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int. J. Cancer 101: 61-68.
75. Kryczek, I., S. Wei, L. Zou, S. Altuwaijri, W. Szeliga, J. Kolls, A. Chang, and W. Zou. 2007. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J. Immunol. 178: 6730-6733. (Pubitemid 46847396)
76. H17 and regulatory T cell differentiation mediated by retinoic acid. Science 317: 256-260.
77. H17 cell differentiation by antagonizing RORγt function. Nature 453: 236-240.
78. + T cells. Curr. Opin. Immunol. 21: 281-285.
79. + T cell lineage differentiation. Immunity 30: 646-655.
80. - T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J. Immunol. 178: 6725-6729.
81. Yang, X. O., R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H. Chang, K. S. Schluns, S. S. Watowich, et al. 2008. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29: 44-56.
82. Voo, K. S., Y. H. Wang, F. R. Santori, C. Boggiano, Y. H. Wang, K. Arima, L. Bover, S. Hanabuchi, J. Khalili, E. Marinova, et al. 2009. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc. Natl. Acad. Sci. USA 106: 4793-4798.
83. Beriou, G., C. M. Costantino, C. W. Ashley, L. Yang, V. K. Kuchroo, C. Baecher-Allan, and D. A. Hafler. 2009. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood 113: 4240-4249.
84. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
85. Numasaki, M., M. Watanabe, T. Suzuki, H. Takahashi, A. Nakamura, F. McAllister, T. Hishinuma, J. Goto, M. T. Lotze, J. K. Kolls, and H. Sasaki. 2005. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J. Immunol. 175: 6177-6189.
86. Tartour, E., F. Fossiez, I. Joyeux, A. Galinha, A. Gey, E. Claret, X. Sastre-Garau, J. Couturier, V. Mosseri, V. Vives, et al. 1999. Interleukin 17, a T-cell-derived cytokine, promotes tumorigenicity of human cervical tumors in nude mice. Cancer Res. 59: 3698-3704.
87. Numasaki, M., J. Fukushi, M. Ono, S. K. Narula, P. J. Zavodny, T. Kudo, P. D. Robbins, H. Tahara, and M. T. Lotze. 2003. Interleukin-17 promotes angiogenesis and tumor growth. Blood 101: 2620-2627.
88. Numasaki, M., M. T. Lotze, and H. Sasaki. 2004. Interleukin-17 augments tumor necrosis factor-α-induced elaboration of proangiogenic factors from fibroblasts. Immunol. Lett. 93: 39-43.
89. Takahashi, H., M. Numasaki, M. T. Lotze, and H. Sasaki. 2005. Interleukin-17 enhances bFGF-, HGF- and VEGF-induced growth of vascular endothelial cells. Immunol. Lett. 98: 189-193. (Pubitemid 40602629)
90. Honorati, M. C., S. Neri, L. Cattini, and A. Facchini. 2006. Interleukin-17, a regulator of angiogenic factor release by synovial fibroblasts. Osteoarthritis Cartilage 14: 345-352.
91. Jeon, S. H., B. C. Chae, H. A. Kim, G. Y. Seo, D. W. Seo, G. T. Chun, N. S. Kim, S. W. Yie, W. H. Byeon, S. H. Eom et al. 2007. Mechanisms underlying TGF-β1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J. Leukocyte Biol. 81: 557-566.
92. Huang, X., and C. Lee. 2003. Regulation of stromal proliferation, growth arrest, differentiation and apoptosis in benign prostatic hyperplasia by TGF-β. Front. Biosci. 8: 740-749. (Pubitemid 39140194)
93. Kehlen, A., K. Thiele, D. Riemann, N. Rainov, and J. Langner. 1999. Interleukin-17 stimulates the expression of IκBα mRNA and the secretion of IL-6 and IL-8 in glioblastoma cell lines. J. Neuroimmunol. 101: 1-6. (Pubitemid 29505167)
94. Waugh, D. J., and C. Wilson. 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14: 6735-6741.
95. Aggarwal, S., and A. L. Gurney. 2002. IL-17: prototype member of an emerging cytokine family. J. Leukocyte Biol. 71: 1-8. (Pubitemid 34062767)
96. Karin, M. 2006. Nuclear factor-κB in cancer development and progression. Nature 441: 431-436.
97. Shalom-Barak, T., J. Quach, and M. Lotz. 1998. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J. Biol. Chem. 273: 27467-27473.
98. Subramaniam, S. V., R. S. Cooper, and S. E. Adunyah. 1999. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem. Biophys. Res. Commun. 262: 14-19.
99. Subramaniam, S. V., L. L. Pearson, and S. E. Adunyah. 1999. Interleukin-17 induces rapid tyrosine phosphorylation and activation of raf-1 kinase in human monocytic progenitor cell line U937. Biochem. Biophys. Res. Commun. 259: 172-177.
100. Hunter, C. A. Act1-ivating IL-17 inflammation. 2007. Nat. Immunol. 8: 232-234.
101. Gaffen, S. L. 2008. An overview of IL-17 function and signaling. Cytokine 43: 402-407.
102. Strieter, R. M., M. D. Burdick, B. N. Gomperts, J. A. Belperio, and M. P. Keane. 2005. CXC chemokines in angiogenesis. Cytokine Growth Factor Rev. 16: 593-609.
103. Moore, B. B., D. A. Arenberg, C. L. Addison, M. P. Keane, P. J. Polverini, and R. M. Strieter. 1998. CXC chemokines mechanism of action in regulating tumor angiogenesis. Angiogenesis 2: 123-134.
104. Arenberg, D. A., S. L. Kunke, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Iannettoni, R. I. Whyte, and R. M. Strieter. 1996. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184: 981-992.
105. Lee, J. W., P. Wang, M. G. Kattah, S. Youssef, L. Steinman, K. DeFea, and D. S. Straus. 2008. Differential regulation of chemokines by IL-17 in colonic epithelial cells. J. Immunol. 181: 6536-6545.
106. Muranski, P., A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. 2008. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112: 362-373.
107. Benchetrit, F., A. Ciree, V. Vives, G. Warnier, A. Gey, C. Sautès-Fridman, F. Fossiez, N. Haicheur, W. H. Fridman, and E. Tartour. 2002. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood. 99: 2114-2121.
108. Jovanovic, D. V., J. A. Di Battista, J. Martel-Pelletier, F. C. Jolicoeur, Y. He, M. Zhang, F. Mineau, and J. P. Pelletier. 1998. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α, by human macrophages. J. Immunol. 160: 3513-3521.
109. Antonysamy, M. A., W. C. Fanslow, F. Fu, W. Li, S. Qian, A. B. Troutt, and A. W. Thomson. 1999. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J. Immunol. 162: 577-584.
110. Hirahara. N., Y. Nio, S. Sasaki, Y. Minari, M. Takamura, C. Iguchi, M. Dong, K. Yamasawa, and K. Tamura. 2001. Inoculation of human interleukin-17 genetransfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 61: 79-89.
111. Kryczek, I., S. Wei, W. Szeliga, L. Vatan, and W. Zou. 2009. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 114: 357-359.
112. + T cells. Immunity 30: 155-167.
113. Lee, Y. K., H. Turner, C. L. Maynard, J. R. Oliver, D. Chen, C. O. Elson, and C. T. Weaver. 2009. Late developmental plasticity in the T helper 17 lineage. Immunity 30: 92-107.
114. Sundrud, M. S., S. M. Grill, D. Ni, K. Nagata, S. S. Alkan, A. Subramanian, and D. Unutmaz. 2003. Genetic reprogramming of primary human T cells reveals functional plasticity in Th cell differentiation. J. Immunol. 171: 3542-3549.